Covid-19 roundup: China's Sinovac goes to Brazil for PhIII; AstraZeneca signs Emergent on for $87M manufacturing deal
Sinovac, the first Chinese biotech to publish animal data on a Covid-19 vaccine, is teaming up with a Brazilian partner to test its candidate in the South American country.
Instituto Butantan is still awaiting clearance from local authorities to kick off the Phase III trial, which will enroll 9,000 people in July. The company will get a license for the vaccine in Brazil should it prove effective.
As new infections in China become a rare occurrence, scientists have run into the bizarre problem of not having enough exposure to really know whether the inoculations are protecting their volunteers.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
